Holiday Notice
PharmaDJ · 09/30/2022
PharmaDJ will take a brief publishing break from October 1 to 9 in observance of China’s National Day holiday.
READ MORE

Latest Articles

NeuShen Therapeutics closes Pre-A financing worth $ 20M; MabPlex
Sarina Yang · 18 hours ago
NeuShen Therapeutics announced the closure of a $20 million Series pre-A financing round led by LAPAM capital. More news from MabPlex.
News
Holiday Notice
PharmaDJ · Yesterday
PharmaDJ will take a brief publishing break from October 1 to 9 in observance of China’s National Day holiday.
News
Simcere and Almirall enter into a licensing agreement for IL-2 mu Fc; JHM Biopharma, Lepu Biopharma, MSD, Sinopharm, Henlius Biotech
Sarina Yang · Yesterday
Almirall will be granted exclusive rights to develop and commercialize SIM0278 for all indications outside of the Greater China region. Simcere will receive a $15 million upfront payment and up to $492 million in milestone payments. More news from JHM Biopharma, Lepu Biopharma, MSD, Sinopharm, Henlius Biotech.
News
More MNCs are partnering with Chinese drugmakers in licensing deals
Shi Yingzi · 2 days ago
August saw eight drug licensing deals, including five in-licensing agreements, an out-licensing deal and two partnerships between domestic companies.
China Deals Tracker
Seagen and Zai Lab announced regional strategic collaboration and licensing agreement for TIVDAK; Jiuzhou Pharma, Joincare Pharmaceutical
Sarina Yang · 2 days ago
Zai Lab announced an exclusive collaboration and license agreement for the development and commercialization of TIVDAK (tisotumab vedotin-tftv) in Greater China. More news from Jiuzhou Pharma, Joincare Pharmaceutical.
News
Xuanzhu Biopharmaceutical files IPO application with the STAR Market; SingMed, MSD, Gluetacs Therapeutics, LongBio Pharma, Hansoh Pharma, BIOHENG, Brii Biosciences
Sarina Yang · 3 days ago
Xuanzhu Biopharmaceutical, Sihuan Pharm’s holding company, has filed for an IPO with the STAR Market to raise RMB 2.47 billion ($345.22 million). More news from SingMed, MSD, Gluetacs Therapeutics, LongBio Pharma, Hansoh Pharma, BIOHENG, Brii Biosciences.
News
Huisheng Biopharmaceutical completes Series A funding to advance diabetes drugs; Guangsheng Zhonglin
Danni Yin · 4 days ago
Huisheng Biopharmaceutical, a non-wholly owned subsidiary of Sihuan Pharmaceutical, announced that it completed Series A financing worth RMB 500 million RMB ($70 million). The round was led by China Life Private Equity Investment, Grand Flight Investment, Yuanyi Jimao Equity Investment and Ginko Capital.
News
Chinese drugmakers scramble to get a head start in the iPSC race
Danni Yin · 5 days ago
Since 2021, Induced multifunctional stem cells (iPSC) have triggered a funding boom and several Chinese companies rushing into the iPSC space.
Feature
Small nucleic acid drug specialist YouJia Bio completes Series A+ funding round; AstraZeneca, MSD, Hepa Thera Bio, Fosun Pharma
Sarina Yang · 8 days ago
YouJia Bio announced the completion of a Series A+ round of financing worth tens of millions of RMB. It was led exclusively by the ChengZhang Group. More news from AstraZeneca, MSD, Hepa Thera Bio, Fosun Pharma.
News
Chimigen Bio closes first round of funding worth RMB 100M to advance immunotherapy; CTTQ Pharma, Inventiva Pharma, Merck
Sarina Yang · 8 days ago
Chimigen Bio has closed an initial funding round worth over 100 million RMB ($14.11 million) led by Lapam Capital and followed by Puhua Capital and Kingfriend Pharma. More news from CTTQ Pharma, Inventiva Pharma, Merck.
News
Copyright © 2016-2022 PharmaDJ .All Rights Reserved.   Suggestions and feedback: Support@PharmaDJ.com   Record/License No.:沪ICP备17054709号-1  
About PharmaDJ | Subscription | Contact Us | Copyright Statement